- Home
- REX vs XERS Comparison
REX vs XERS Comparison
Compare REX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- XERS
- Stock Information
- Founded
- REX 1980
- XERS 2005
- Country
- REX United States
- XERS United States
- Employees
- REX N/A
- XERS N/A
- Industry
- REX Major Chemicals
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- REX Industrials
- XERS Health Care
- Exchange
- REX Nasdaq
- XERS Nasdaq
- Market Cap
- REX 1.1B
- XERS 1.3B
- IPO Year
- REX N/A
- XERS 2018
- Fundamental
- Price
- REX $31.78
- XERS $9.91
- Analyst Decision
- REX Strong Buy
- XERS Strong Buy
- Analyst Count
- REX 1
- XERS 7
- Target Price
- REX $25.00
- XERS $9.43
- AVG Volume (30 Days)
- REX 164.4K
- XERS 2.2M
- Earning Date
- REX 12-02-2025
- XERS 11-06-2025
- Dividend Yield
- REX N/A
- XERS N/A
- EPS Growth
- REX N/A
- XERS N/A
- EPS
- REX 1.49
- XERS N/A
- Revenue
- REX $650,008,000.00
- XERS $246,025,000.00
- Revenue This Year
- REX $3.27
- XERS $43.89
- Revenue Next Year
- REX $17.11
- XERS $20.40
- P/E Ratio
- REX $21.63
- XERS N/A
- Revenue Growth
- REX N/A
- XERS 35.62
- 52 Week Low
- REX $16.73
- XERS $2.82
- 52 Week High
- REX $33.77
- XERS $10.03
- Technical
- Relative Strength Index (RSI)
- REX 38.95
- XERS 73.40
- Support Level
- REX $31.14
- XERS $9.11
- Resistance Level
- REX $32.38
- XERS $9.97
- Average True Range (ATR)
- REX 0.92
- XERS 0.38
- MACD
- REX 0.57
- XERS 0.05
- Stochastic Oscillator
- REX 38.97
- XERS 88.79
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).